Leflunomide 13C6

[13C6]-Leflunomide is a stable isotope-labeled form of Leflunomide, a medication used to treat rheumatoid arthritis. The stable isotope labeling is achieved by replacing six carbon atoms in the molecule with the heavier carbon-13 isotope. This labeling allows for the tracking and identification of the drug molecule during metabolic studies and drug development research. Leflunomide works by inhibiting the activity of an enzyme called dihydroorotate dehydrogenase, which is involved in the synthesis of DNA and RNA. This inhibition prevents the proliferation and activation of immune cells, thereby reducing inflammation in the joints and improving symptoms in patients with rheumatoid arthritis. [13C6]-Leflunomide is primarily used in pharmacokinetic studies to assess the metabolism, distribution, and excretion of the drug in the body. The stable isotope labeling allows for the drug to be distinguished from endogenous compounds and other drugs, making it easier to track its movement through the body. This information can be used to optimize dosing regimens, identify potential drug interactions, and improve drug safety and efficacy. In addition to its pharmacokinetic applications, [13C6]-Leflunomide can also be used in drug discovery research, where it is used to identify and optimize new drug candidates. By tracking the labeled drug molecule, researchers can gain insight into the molecular mechanisms of drug action and identify potential targets for new drugs. Overall, [13C6]-Leflunomide is a valuable tool for pharmacological and biochemical research, providing crucial insights into the metabolism and pharmacokinetics of Leflunomide and other drugs.